复发性流产患者中抗核抗体与妊娠预后的关联
该回顾性队列研究纳入2006至2019年名古屋市立大学医院的1021例不明原因复发性流产女性,比较抗核抗体(ANA)阳性与阴性者后续活产率。在1:40、1:80、1:160稀释度下,两组活产率均无显著差异,调整年龄和BMI后仍无差异。作者认为ANA检测对预测不明原因复发性流产患者未来妊娠丢失无帮助。
要点
- 不明原因复发性流产患者妊娠试验阳性后活产概率高(>70%),ANA阳性与阴性者相似。
- 1:40稀释度下活产率ANA阳性组72.5% vs 阴性组73.2%,OR=0.97(95%CI=0.72-1.29)。
- 排除胚胎非整倍体流产、生化妊娠丢失和异位妊娠后,各稀释度下两组活产率仍无显著差异。
核心结论
- 不明原因复发性流产女性妊娠试验阳性后活产概率>70%,ANA阳性与阴性者相似,不受截断值影响。
- 作者认为ANA检测对预测不明原因复发性流产患者未来妊娠丢失无帮助。
研究设计与样本
- 2006至2019年在名古屋市立大学医院开展的回顾性队列研究,纳入1021例不明原因复发性流产女性。
- 妊娠前进行子宫输卵管造影或三维超声、双方染色体分析、抗磷脂抗体、ANA、甲状腺功能减退和糖尿病血液检查。
- ANA采用Hep-2细胞玻片间接免疫荧光法检测,截断稀释度为1:40,并按荧光染色模式分类。
- 排除抗磷脂抗体综合征、双方染色体异常和子宫异常患者后比较ANA阳性与阴性组的活产率。
主要发现
- 1:40稀释度下,后续活产率ANA阳性组72.5%(256/353)vs ANA阴性组73.2%(489/668),OR=0.97(95%CI=0.72-1.29)。
- 1:40稀释度下排除胚胎非整倍体流产、生化妊娠丢失和异位妊娠后,活产率ANA阳性组92.8%(256/276)vs ANA阴性组93.0%(489/526),OR=0.97(95%CI=0.55-1.70)。
- 1:80稀释度下,后续活产率ANA阳性组75.0%(87/116)vs ANA阴性组72.7%(658/905),OR=1.13(95%CI=0.72-1.76)。
- 1:80稀释度下排除胚胎非整倍体流产、生化妊娠丢失和异位妊娠后,活产率ANA阳性组89.7%(87/97)vs ANA阴性组93.3%(658/705),OR=0.62(95%CI=0.30-1.27)。
- 1:160稀释度下,后续活产率ANA阳性组82.4%(28/34)vs ANA阴性组72.6%(717/987),OR=1.76(95%CI=0.72-4.29);排除后活产率ANA阳性组93.3%(28/30)vs ANA阴性组92.9%(717/772),OR=1.07(95%CI=0.25-4.63)。
关键数值与推荐
- ESHRE复发性流产指南指出「ANA检测可考虑用于解释目的」。
- ANA截断稀释度分别为1:40、1:80、1:160,按荧光染色模式分为均质型、斑点型、核仁型、着丝粒型、周边型、胞质型和其他型。
临床怎么用
- 作者认为ANA检测对预测不明原因复发性流产女性未来妊娠丢失无帮助。
- ESHRE指南指出ANA检测可考虑用于解释目的。
局限性
- 未设立健康对照组,无法比较健康对照与复发性流产患者的ANA阳性率。
- ANA阳性与阴性组间年龄(1:40稀释度)和BMI(1:160稀释度)存在显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can antinuclear antibodies (ANA) affect the subsequent live birth rate (LBR) in patients with unexplained recurrent pregnancy loss (RPL) in the absence of antiphospholipid antibodies (aPL)? SUMMARY ANSWER: Women with unexplained RPL have a high probability of live birth following a positive pregnancy test (>70%), being similar between those with positive and negative ANA testing, regardless of the cut-off value. WHAT IS KNOWN ALREADY: The RPL guidelines of the ESHRE state that 'ANA testing can be considered for explanatory purposes'. However, there have been a limited number of studies on this issue and sample sizes have been small, and the impact of ANA on the pregnancy prognosis is unclear. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study was conducted at Nagoya City University Hospital between 2006 and 2019. The study included 1021 women with RPL without known cause. PARTICIPANTS/MATERIALS, SETTING, METHODS: Hysterosalpingography or 3D-ultrasound, chromosome analysis for both partners, blood tests for aPL, ANA, hypothyroidism, and diabetes mellitus were performed before a subsequent pregnancy. ANAs were measured by indirect immunofluorescence on Hep-2 cell slides. The cutoff dilution used was 1:40. In addition, patients were classified according to the ANA pattern on immunofluorescence staining: homogeneous, speckled, nucleolar, centromeric, peripheral, cytoplasmic, and others. LBRs were compared between ANA-positive and ANA-negative patients after excluding patients with antiphospholipid antibody syndrome, an abnormal chromosome in either partner and a uterine anomaly. MAIN RESULTS AND THE ROLE OF CHANCE: Considering the cut-off value = 1:40 dilution, the subsequent LBRs were 72.5% (256/353) for the ANA-positive group and 73.2% (489/668) for the ANA-negative group; odds ratio (OR) = 0.97, 95% CI = 0.72-1.29. After excluding the miscarriages occurring from embryonic aneuploidy, the biochemical pregnancy losses, and the ectopic pregnancies, LBRs were 92.8% (256/276) for the ANA-positive group and 93.0% (489/526) for the ANA-negative group: OR = 0.97 (95% CI = 0.55-1.70). Considering the cut-off value = 1:80 dilution, the subsequent LBRs were 75.0% (87/116) for the ANA-positive group and 72.7% (658/905) for the ANA-negative group; OR = 1.13 (95% CI = 0.72-1.76). After excluding the miscarriages occurring from embryonic aneuploidy, the biochemical pregnancy losses, and the ectopic pregnancies, LBRs were 89.7% (87/97) for the ANA-positive group and 93.3% (658/705) for the ANA-negative group: OR = 0.62 (95% CI = 0.30-1.27). Considering the cut-off value = 1:160 dilution, the subsequent LBRs were 82.4% (28/34) for the ANA-positive group and 72.6% (717/987) for the ANA-negative group; OR = 1.76 (95% CI = 0.72-4.29). After excluding the miscarriages occurring from embryonic aneuploidy, the biochemical pregnancy losses, and the ectopic pregnancies, LBR were 93.3% (28/30) for the ANA-positive group and 92.9% (717/772) for the ANA-negative group: OR = 1.07 (95% CI = 0.25-4.63). There was no difference in LBR between the 2 groups before or after adjustment for age and BMI, but ANA-positive patients were significantly older than ANA-negative patients when using the 1:40 dilution, and ANA-positive patients had significantly lower BMIs than ANA-negative patients when using the 1:80 dilution. LIMITATIONS, REASONS FOR CAUTION: A healthy control group was not established, making it impossible to compare ANA positivity rates between healthy controls and RPL patients. There were significant differences in age (1:40 dilution) and BMI (1:160 dilution) between the ANA-positive and ANA-negative groups. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest that ANA testing is not useful to predict future pregnancy loss in women with RPL without known cause. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by MEXT Promotion of Distinctive Joint Research Center Program, Grant Number JPMXP0621467963 and used for English proofreading costs. There are no competing interests for all authors. TRIAL REGISTRATION NUMBER: N/A.
引用
- Yoshihara H, Goto S, Kitaori T, et al. Association between antinuclear antibodies and pregnancy prognosis in recurrent pregnancy loss patients. Hum Reprod. 2025. PMID: 39706916. doi:10.1093/humrep/deae280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。